Brasada Capital Management LP Has $6.51 Million Position in Solventum Corporation $SOLV

Brasada Capital Management LP increased its position in Solventum Corporation (NYSE:SOLV) by 32.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 82,383 shares of the company’s stock after buying an additional 20,138 shares during the period. Solventum accounts for 1.1% of Brasada Capital Management LP’s portfolio, making the stock its 28th largest holding. Brasada Capital Management LP’s holdings in Solventum were worth $6,510,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in SOLV. Hilltop National Bank increased its holdings in Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after buying an additional 129 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new position in Solventum in the third quarter worth approximately $25,000. JNBA Financial Advisors increased its holdings in Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after buying an additional 228 shares during the last quarter. CYBER HORNET ETFs LLC acquired a new position in Solventum in the second quarter worth approximately $28,000. Finally, City State Bank increased its holdings in Solventum by 166.7% in the fourth quarter. City State Bank now owns 384 shares of the company’s stock worth $30,000 after buying an additional 240 shares during the last quarter.

Solventum Stock Down 0.5%

Shares of Solventum stock opened at $78.85 on Friday. The stock has a market capitalization of $13.66 billion, a P/E ratio of 9.66, a PEG ratio of 1.22 and a beta of 0.69. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The stock has a 50 day moving average price of $72.50 and a two-hundred day moving average price of $75.26. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $88.20.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s revenue was down 3.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities analysts expect that Solventum Corporation will post 6.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on SOLV shares. Wedbush started coverage on Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price objective on the stock. Stifel Nicolaus decreased their target price on Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. BTIG Research reaffirmed a “buy” rating and set a $89.00 target price on shares of Solventum in a research report on Wednesday, May 6th. KeyCorp upped their target price on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Eight investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Solventum currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.